STOCK TITAN
  1. Home
  2. News
  3. DRIO

DarioHealth Corp - DRIO STOCK NEWS

Welcome to our dedicated news page for DarioHealth (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on DarioHealth.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DarioHealth's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DarioHealth's position in the market.

News
Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes
Rhea-AI Summary
DarioHealth Corp. published a new peer-reviewed study in the Journal of Internet Medicine, demonstrating a significant reduction in blood glucose levels and BMI for members using Dario's integrated platform to manage weight alongside diabetes. The study highlights the importance of addressing weight in managing Type 2 diabetes and the positive impact of Dario's cardiometabolic solution on clinical outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution
Rhea-AI Summary
DarioHealth Corp. (Nasdaq: DRIO) has secured two new contracts to provide integrated chronic condition management solutions for two employers, a national supply chain company, and a regional education organization. The contracts aim to improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension, and weight management needs. Dario's cardiometabolic suite, combined with intelligent technologies and data insights, offers highly personalized experiences to keep members engaged for optimal results. Employees taking a GLP-1 medication will benefit from tailored support for long-term behavior change.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
none
-
News
Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health
Rhea-AI Summary
DarioHealth Corp. (DRIO) announces two new studies showcasing the effectiveness of digital stress management programs for teens. A Randomized Controlled Trial (RCT) revealed significant reductions in perceived stress, brooding, and loneliness in teens utilizing a Digital Mental Health Intervention (DMHI). Another study highlighted the positive impact of relaxation tools like breathing exercises and Cognitive Behavioral Therapy (CBT) videos on stress reduction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
News
Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health
Rhea-AI Summary
DarioHealth Corp. secures contracts with two national employers to provide integrated chronic condition management solutions, focusing on cardiometabolic health, musculoskeletal, and behavioral health support, including for GLP-1 medication users.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.14%
Tags
none
-
News
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
Rhea-AI Summary
DarioHealth Corp. reported a full-year 2023 revenue of $20.4 million, reflecting a decrease from 2022 due to managed B2C revenue decrease and B2B2C revenue increase. The company saw a 39% year-over-year growth in core B2B2C business. Operating expenses decreased sequentially, and the company signed multiple customers onto the Aetna platform. The acquisition of Twill, Inc. is expected to enhance profitability and revenue scale.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
earnings
-
News
DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH
Rhea-AI Summary
DarioHealth Corp. (DRIO) to release financial results for Q4 2023 on March 28th, 2024, and host a conference call with CEO and President. Dial-in and webcast details provided for participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
conferences earnings
News
New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications
Rhea-AI Summary
DarioHealth Corp. presented two new clinical studies at ATTD 2024, showcasing the impact of its integrated cardiometabolic solution on weight management and diabetes, as well as improving awareness of flu vaccines in members with Type 1 and Type 2 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.6%
Tags
none
-
News
DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE
Rhea-AI Summary
DarioHealth Corp. (DRIO) executives to participate in Cowen 44th Annual Healthcare Conference. Erez Raphael and Rick Anderson to hold a fireside chat on March 6th, 2024. Webcast link provided for live viewing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
conferences
-
News
Dario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions
Rhea-AI Summary
DarioHealth Corp. (DRIO) acquires Twill, Inc., expecting to nearly double pro forma revenues in 2023. The acquisition is immediately accretive to revenue and gross margins, accelerating the path to profitability. Dario also prices a $22.4 million equity financing concurrently with the acquisition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.8%
Tags
acquisition
News
Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support
Rhea-AI Summary
DarioHealth Corp. (NASDAQ: DRIO) announces a new contract with a regional union to provide its cardiometabolic solution to food industry workers living with diabetes, pre-diabetes, and weight management needs, as well as those taking GLP-1 or anti-obesity medication. The company's unique approach has been successful in engaging employees in healthier behaviors, leading to long-term results. The President of Dario, Rick Anderson, is optimistic about the company's strong start in 2024, with growing demand and the launch of Aetna and several previously contracted employers in the first quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.91%
Tags
none
Stock DRIO logo
DarioHealth Corp

Nasdaq:DRIO

DRIO Rankings

#4805 Ranked by Market Cap
#5153 Ranked by Stock Gains
N/A Ranked by Dividends

DRIO Stock Data

36.21M
23.92M
14.81%
29.43%
4.63%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
New York

About DRIO

DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform.